$RLFTF Branden DD (opinion) post -Ya-h00 - Many people don’t realize how many high flow nasal cannula covid patients there are in hospitals. This isn’t just a tiny, insignificant subgroup of hospitalized covid patient.
There are literally designated floors in hospitals across the country made up entirely of noninvasive ventilated covid patients.
Multiple floors even within the same hospital. Many hospitals require these patients to only go to the intensive care unit but some allow for them to go to what’s called intermediate care units.
These high flow nasal cannula (hfnc) patients sit here often for weeks or even longer with the hope that respiratory failure will improve so we can titrate that fi02(oxygen concentration) down accordingly to a nasal cannula and then to room air allowing for discharge home.
(Sometimes home on 2 ltr nasal cannula). Some patients do well and you’re able to titrate down, however a ton of hfnc patients don’t do well once their admitted.
Their disease process worsens and you have to titrate fiO2 up on the hfnc. Sometimes they decompensate to the point where they need to be mechanically ventilated.
But Imagine if we give zyesami to all of these patients the minute they require high volumes of oxygen such as a hfnc.
You come into the emergency room, you’re diagnosed with covid pneumonia requiring hfnc at 70% fiO2, we’re going to immediately start a zyesami infusion and send you up to an intercare or icu bed.
11 days isn’t insignificant, 11 days is HUGE.
Something biologically is happening to decrease that hospital time and I guarantee you if their hospital stay is shortened that significantly, then respiratory failure will be resolving more frequently.
I want to know how many zyesami hfnc patients DONT have to get intubated because they got our drug.
Excited stuff on the horizon guys. EUA within our future.
